Brief: Supernus Pharmaceuticals Q1 Adjusted Operating Earnings USD 22.3 Million Vs. IBES Estimate USD 22.9 Million
08/05/2024 21:06
May 08 (Reuters) - Supernus Pharmaceuticals Q1 product sales USD 138.4 million. * Q1 adjusted revenue USD 100.7 million vs. IBES estimate USD 145.8 million * Q1 operating earnings USD -3.153 million * outlook FY revenue USD 580-620 million * outlook FY adjusted operating earnings USD 80-110 million
Recent news on Supernus Pharmaceuticals
See all newsHuron Consulting poised to hit fresh record ahead of S&P SmallCap addition
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing